drugset / Trial / NCT03387904
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).
Timeline
- Start
- 2019-01-13
- Primary completion
- 2021-12-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |
| Comparator | Irinotecan | Small molecule | — | Intravenous |